For treatment-naïve adults with chronic hepatitis B and normal renal function, both Tenofovir disoproxil fumarate (TDF) and Entecavir are equally preferred first-line agents with comparable efficacy and safety profiles.
Primary Recommendation
The 2018 AASLD guidelines explicitly state that tenofovir and entecavir are preferred because of their potency and minimal risk of resistance, decompensation, and serious side effects 1. The guidelines suggest no preference between entecavir or tenofovir (TDF) regarding potential long-term risks of renal and bone complications in the general population 1. Both agents demonstrate:
- High genetic barrier to resistance (entecavir: 1.2% resistance at 5 years; tenofovir: 0% resistance at 5 years) 1, 2
- Comparable virologic suppression rates (90-93% for both agents) 1, 2
- Similar long-term efficacy in achieving undetectable HBV DNA 2, 3
Key Differentiating Factors
When to Prefer Entecavir:
Patients with or at risk of renal dysfunction or metabolic bone disease should receive entecavir over TDF 4. The 2022 KASL guidelines specifically recommend entecavir, tenofovir alafenamide (TAF), or besifovir over TDF in treatment-naïve patients with:
- eGFR < 60 mL/min/1.73 m²
- Dipstick proteinuria or urine albumin/creatinine > 30 mg/g
- Low serum phosphate (< 2.5 mg/dL)
- Pre-existing osteoporosis or bone disease 4
Recent real-world data from Vietnam showed that entecavir improved renal function (mean eGFR change +3.02 mL/min, p=0.002) while TDF caused mild decline (-3.84 mL/min, p<0.001) over 48 weeks 3.
When to Prefer Tenofovir (TDF):
TDF may be preferable in patients with active hepatic inflammation based on biochemical response patterns. TDF achieved:
- Significantly higher ALT normalization at Week 24 (72.9% vs 59.9%, p=0.01) and Week 48 (84.0% vs 69.5%, p=0.001) compared to entecavir 3
- More frequent quantitative HBsAg reduction (>10% decline in 63% vs 55.8% at 12 months) 5
For pregnant women requiring treatment, TDF is specifically preferred over entecavir to minimize resistance risk during the third trimester 1, 6.
Monitoring Requirements
For TDF-treated patients:
Mandatory renal safety monitoring includes serum creatinine, phosphorus, urine glucose, and urine protein assessed before treatment and at least annually (more frequently if high-risk) 1, 7.
For both agents:
- HBV DNA every 3-6 months until virologic response achieved, then every 6-12 months 2
- HBsAg quantification every 12 months 2
- Non-invasive fibrosis assessment every 12-24 months 2
Important Clinical Considerations
If TDF-associated renal dysfunction or bone disease develops, switch to TAF or entecavir with consideration for any previously known drug resistance 1. The 2022 KASL data demonstrates that switching from TDF to TAF or entecavir can recover renal function and bone mineral density to baseline 4.
Dose adjustment is required for both agents when creatinine clearance falls below 50 mL/min 1, 7. TDF should not be used if creatinine clearance < 15 mL/min without dialysis 4.
Controversial HCC Risk Data
Recent meta-analyses from Asian cohorts suggested TDF may reduce HCC risk more than entecavir, but European cohort studies found no significant difference 2. The 2025 EASL guidelines state there is currently no clear recommendation favoring TDF over entecavir for HCC risk reduction due to conflicting data and absence of mechanistic explanation 2. Treatment selection should prioritize tolerability, comorbidities, and cost rather than unproven HCC benefits.
Practical Algorithm
For treatment-naïve CHB patients with normal renal function:
- Check baseline: eGFR, serum phosphorus, urine protein, bone density (if risk factors present)
- If eGFR ≥60 and no bone/renal risk factors: Either TDF or entecavir (consider TDF if high ALT/active inflammation)
- If eGFR <60 or renal/bone risk factors present: Entecavir (or TAF if available)
- If pregnant or planning pregnancy: TDF (third trimester initiation)
- Monitor renal function closely if TDF selected, with readiness to switch if dysfunction develops
Both agents achieve the primary goal of durable HBV DNA suppression with minimal resistance, making either choice appropriate for most patients when individualized to specific clinical contexts 1, 2.